Status:
COMPLETED
Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis
Lead Sponsor:
Fougera Pharmaceuticals Inc.
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
3-17 years
Phase:
PHASE2
Brief Summary
The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis
Detailed Description
Treatment medication will be administered topically, twice a day for 4 weeks.
Eligibility Criteria
Inclusion
- Clinical diagnosis of Atopic Dermatitis
- Good health with the exception of Atopic Dermatitis
- Percent body surface area minimum requirements
Exclusion
- Subjects who are pregnant, nursing, or planning a pregnancy
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT01232543
Start Date
November 1 2010
End Date
November 1 2011
Last Update
April 11 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fougera Pharmaceuticals Inc.
Melville, New York, United States, 11747